Lack of effect of cisplatin on i. v. L-PAM plasma pharmacokinetics in ovarian cancer patients

M. Zucchetti, M. D'Incalci, Y. Willems, F. Cavalli, C. Sessa

Research output: Contribution to journalArticlepeer-review


Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t1/2β), plasma clearance (Clp), and volume of distribution (Vdβ) of L-PAM were, respectively: 46.4±6.7 min, 20.5±3.7 l/m2, and 306.8±34.4 ml/min per square meter. When L-PAM was inoculated 24 h after DDP, t1/2β, Clp, and Vdβ were 47.5±6.3 min, 20.4±2.8 l/m2, and 322.0±54.1 ml/min per square meter. Thus, DDP pretreatment does not significantly affect L-PAM pharmacokinetics. Regression analysis showed a significant correlation between the L-PAM elimination rate constant (β) and renal function assessed by creatinine clearance. One patient who received this sequence of treatment for six courses showed a threefold decrease of L-PAM clp after the last treatment. The reported high myelotoxicity of the combination of DDP and L-PAM when DDP was given 24 h before L-PAM cannot be attributed to DDP-induced changes in L-PAM kinetics but might to some extent be related to a loss of renal function consequent to many courses of treatment.

Original languageEnglish
Pages (from-to)87-89
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number1
Publication statusPublished - Jul 1988

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Lack of effect of cisplatin on i. v. L-PAM plasma pharmacokinetics in ovarian cancer patients'. Together they form a unique fingerprint.

Cite this